Skip to main content

Advertisement

SpringerLink
Log in

Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Adult acute lymphoblastic leukemia (ALL) is a heterogeneous disease with distinct biologic and prognostic subgroups. The treatment of adults with ALL has evolved largely from the therapy developed for childhood ALL and, despite differences across regimens, can be broadly classified as including induction, consolidation, maintenance, and central nervous system prophylaxis. Although there has been marked improvement in the outcomes for pediatric patients with ALL, the same success has not yet been realized for adult patients. Some of this difference can be attributed to a greater incidence of unfavorable cytogenetic subtypes in adults than in children. In addition, the ability to tolerate intensive regimens likely plays a role. This article reviews the classification, prognostic features, current treatment programs, and new advances as applied to adult patients with newly diagnosed ALL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10–30.

    Article  PubMed  Google Scholar 

  2. Lamanna N, Weiss M: Treatment options for newly diagnosed patients with adult acute lymphoblastic leukemia. Curr Hematol Rep 2004, 3:40–46.

    PubMed  Google Scholar 

  3. Hoelzer D, Gokbuget N, Ottmann O, et al.: Acute lymphoblastic leukemia. Hematology (Am Soc Hematol Educ Program) 2002, 162–192.

  4. Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med 2004, 350:1535–1548.

    Article  PubMed  CAS  Google Scholar 

  5. Soussain C, Patte C, Ostronoff M, et al.: Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 1995, 85:664–674.

    PubMed  CAS  Google Scholar 

  6. Thomas DA, Cortes J, O’Brien S et al.: Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol 1999, 17:2461–2470.

    PubMed  CAS  Google Scholar 

  7. Lee EJ, Petroni GR, Schiffer CA et al.: Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 2001, 19:4014–4022.

    PubMed  CAS  Google Scholar 

  8. Lugo TG, Pendergast AM, Muller AJ, Witte ON: Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 247:1079–1082.

    Article  PubMed  CAS  Google Scholar 

  9. Scandura JM: Advances in the molecular genetics of acute leukemia. Curr Oncol Rep 2005, 7:323–332.

    Article  PubMed  CAS  Google Scholar 

  10. Sutcliffe MJ, Shuster JJ, Sather HN, et al.: High concordance from independent studies by the Children’s Cancer Group (CCG) and Pediatric Oncolog y Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI standard-risk B-precursor acute lymphoblastic leukemia: a Children’s Oncolog y Group (COG) initiative. Leukemia 2005, 19:734–740.

    Article  PubMed  CAS  Google Scholar 

  11. Groupe Français de Cytog’en’etique H’ematologique:Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings and outcome. A collaborative study of the Group Français de Cytog’en’etique H’ematologique. Blood 1996, 87:3135–3142.This paper demonstrates karyotypic differences between adult and childhood ALL and the prognostic implications of karyotypes.

    Google Scholar 

  12. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001.

  13. Hecht JL, Aster JC: Molecular biology of Burkitt’s lymphoma. J Clin Oncol 2000, 18:3707–3721.

    PubMed  CAS  Google Scholar 

  14. Weng AP, Ferrando AA, Lee W, et al.: Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269–271.This article reports common activating mutations of NOTCH1 and presents a rationale for a new clinical strateg y for the treatment of T-cell ALL.

    Article  PubMed  CAS  Google Scholar 

  15. Arico M, Valsecchi MG, Camitta B, et al.: Outcome of treatment in children with Philadelphia chromosome -positive acute lymphoblastic leukemia. N Engl J Med 2000, 342:998–1006.

    Article  PubMed  CAS  Google Scholar 

  16. Chessells JM, Hall E, Prentice HG, et al.: The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties. Leukemia 1998, 12:463–473.

    Article  PubMed  CAS  Google Scholar 

  17. Ohno R: Current progress in the treatment of adult acute leukemia in Japan. Jpn J Clin Oncol 1993, 23:85–97.

    PubMed  CAS  Google Scholar 

  18. Weiss MA, Heffner L, Lamanna N, et al., for the ALL-4 Consortium: A randomized trial of cytarabine with high-dose mitoxantrone compared to a standard vincristine/prednisone-based regimen as induction therapy for adult patients with ALL [abstract]. J Clin Oncol (Meeting Abstracts) 2005, 23:6516.

    Google Scholar 

  19. Gaynor J, Chapman D, Little C, et al.: A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J Clin Oncol 1988, 6:1014–1030.One of two "classic" papers on prognostic factors in adult ALL.

    PubMed  CAS  Google Scholar 

  20. Hoelzer D, Thiel E, Loffler H, et al.: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988, 71:123–131. One of two "classic" papers on prognostic factors in adult ALL.

    PubMed  CAS  Google Scholar 

  21. Boucheix C, David B, Sebban C et al.: Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood 1994, 84:1603–1612.

    PubMed  CAS  Google Scholar 

  22. Den Boer ML, Harms DO, Pieters R, et al.: Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003, 21:3262–3268.

    Article  CAS  Google Scholar 

  23. Schauer P, Arlin ZA, Mertelsmann R, et al.: Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols. J Clin Oncol 1983, 1:462–470. The first major paper to demonstrate that adult ALL is a curable neoplasm.

    PubMed  CAS  Google Scholar 

  24. Hoelzer D, Thiel E, Loffler H, et al.: Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults. Blood 1984, 64:38–47.

    PubMed  CAS  Google Scholar 

  25. Kantarjian HM, O’Brien S, Smith TL, et al.: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000, 18:547–561.

    PubMed  CAS  Google Scholar 

  26. Linker C, Damon L, Ries C, Navarro W: Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:2464–2471.

    Article  PubMed  CAS  Google Scholar 

  27. Larson R A, Dodge RK, Burns CP, et al.: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811. Blood 1995, 85:2025–2037.

    PubMed  CAS  Google Scholar 

  28. Thomas X, Danaila C, Le QH, et al.: Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia 2001, 15:1811–1822.

    PubMed  CAS  Google Scholar 

  29. Annino L, Vegna ML, Camera A, et al.: Treatment of adult acute lymphoblastic leukemia (ALL): long-term followup of the GIMEMA ALL 0288 randomized study. Blood 2002, 99:863–871.

    Article  PubMed  CAS  Google Scholar 

  30. Takeuchi J, Kyo T, Naito K, et al.: Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study. Leukemia 2002, 16:1259–1266.

    Article  PubMed  CAS  Google Scholar 

  31. Gottlieb AJ, Weinberg V, Ellison RR, et al.: Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. Blood 1984, 64:267–274.

    PubMed  CAS  Google Scholar 

  32. Weiss M, Maslak P, Feldman E, et al.: Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol 1996, 14:2480–2485.This article shows the efficacy of a novel approach to ALL induction therapy with high-dose mitoxantrone and cytarabine. This study led to the recently completed randomized phase III clinical trial comparing the novel regimen to a standard induction program.

    PubMed  CAS  Google Scholar 

  33. Fiere D, Extra JM, David B, et al.: Treatment of 218 adult acute lymphoblastic leukemias. Semin Oncol 1987, 14:64–66.

    PubMed  CAS  Google Scholar 

  34. Toyoda Y, Manabe A, Tsuchida M, et al.: Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000, 18:1508–1516.

    PubMed  CAS  Google Scholar 

  35. Schrappe M, Reiter A, Zimmermann M, et al.: Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000, 14:2205–2222.

    Article  PubMed  CAS  Google Scholar 

  36. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Childhood ALL Collaborative Group. Lancet 1996, 347:1783–1788.

  37. Cassileth PA, Andersen JW, Bennett JM, et al.: Adult acute lymphocytic leukemia: the Eastern Cooperative Oncolog y Group experience. Leukemia 1992, 6(Suppl 2):178–181.

    PubMed  Google Scholar 

  38. Cuttner J, Mick R, Budman DR, et al.: Phase III trial of brief intensive treatment of adult acute lymphocytic leukemia comparing daunorubicin and mitoxantrone: a CALGB Study. Leukemia 1991, 5:425–431.

    PubMed  CAS  Google Scholar 

  39. Dekker AW, van’t Veer MB, Sizoo W, et al.: Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group. J Clin Oncol 1997, 15:476–482.

    PubMed  CAS  Google Scholar 

  40. Scheinberg DA, Maslak PG, Weiss MA: Acute leukemias. In Cancer: Principles and Practice of Oncology, edn 7. Edited by DeVita V T Jr, Hellman S, Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins; 2005:2088–2116.

    Google Scholar 

  41. Kantarjian HM, Walters RS, Smith TL, et al.: Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 1988, 72:1784–1789.

    PubMed  CAS  Google Scholar 

  42. Omura GA, Moffitt S, Vogler WR, Salter MM: Combination chemotherapy of adult acute lymphoblastic leukemia with randomized central nervous system prophylaxis. Blood 1980, 55:199–204.

    PubMed  CAS  Google Scholar 

  43. Burger B, Zimmermann M, Mann G, et al.: Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. J Clin Oncol 2003, 21:184–188.

    Article  PubMed  Google Scholar 

  44. Sebban C, Lepage E, Vernant JP, et al.: Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol 1994, 12:2580–2587.The randomized trial showed no benefit for allogeneic or autologous transplantation in first complete remission for adults with ALL.

    PubMed  CAS  Google Scholar 

  45. Zhang MJ, Hoelzer D, Horowitz MM, et al.: Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. Ann Intern Med 1995, 123:428–431.

    PubMed  CAS  Google Scholar 

  46. Dombret H, Gabert J, Boiron JM et al.: Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial. Blood 2002, 100:2357–2366. The best evidence to date that allogeneic transplantation improves the outcome for patients with Ph+ and high-risk ALL.

    Article  PubMed  CAS  Google Scholar 

  47. Kiehl MG, Kraut L, Schwerdtfeger R, et al.: Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. J Clin Oncol 2004, 22:2816–2825.This study found similar outcomes for patients who received matched related or unrelated allografts, potentially increasing thetransplantation options for high-risk patients.

    Article  PubMed  Google Scholar 

  48. Rocha V, Labopin M, Sanz G, et al.: Transplants of umbilicalcord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004, 351:2276–2285.

    Article  PubMed  CAS  Google Scholar 

  49. Laughlin MJ, Eapen M, Rubinstein P, et al.: Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004, 351:2265–2275.

    Article  PubMed  CAS  Google Scholar 

  50. Brisco J, Hughes E, Neoh SH, et al.: Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. Blood 1996, 87:5251–5256.

    PubMed  CAS  Google Scholar 

  51. Mortuza FY, Papaioannou M, Moreira IM, et al.: Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:1094–1104.

    Article  PubMed  Google Scholar 

  52. Vidriales MB, Perez JJ, Lopez-Berges MC, et al.: Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003, 101:4695–4700.

    Article  PubMed  CAS  Google Scholar 

  53. Bruggemann M, Raff T, Flohr T, et al.: Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107:1116–1123.Although this study highlights the limitations of minimal residual disease (MRD) evaluation, it demonstrates that MRD can be an important prognostic tool in adults with ALL.

    Article  PubMed  CAS  Google Scholar 

  54. Ottmann OG, Druker BJ, Sawyers CL, et al.: A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002, 100:1965–1971.

    Article  PubMed  CAS  Google Scholar 

  55. Thomas DA, Faderl S, Cortes J, et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004, 103:4396–4407.Although the effects of imatinib are less dramatic in Ph+ ALL than in CML, the combination of imatinib and chemotherapy appears to have important clinical benefit for these patients.

    Article  PubMed  CAS  Google Scholar 

  56. Yanada M, Takeuchi J, Sugiura I, et al.: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460–466.

    Article  PubMed  CAS  Google Scholar 

  57. Lee KH, Lee JH, Choi SJ, et al.: Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005, 19:1509–1516.

    Article  PubMed  CAS  Google Scholar 

  58. Graux C, Cools J, Melotte C, et al.: Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. Nat Genet 2004, 36:1084–1089.

    Article  PubMed  CAS  Google Scholar 

  59. Boissel N, Auclerc MF, Lheritier V, et al.: Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003, 21:774–780.This provocative paper is the first of four recent studies indicating that young adults benefit from treatment with more aggressive "pediatric-style" regimens.

    Article  PubMed  Google Scholar 

  60. de Bont JM, Holt B, Dekker AW, et al.: Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004, 18:2032–2035.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leukemia Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, 10021, New York, NY, USA

    Nicole Lamanna MD

Authors
  1. Heather Landau MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicole Lamanna MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicole Lamanna MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Landau, H., Lamanna, N. Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults. Curr Hematol Malig Rep 1, 171–179 (2006). https://doi.org/10.1007/s11899-996-0005-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-996-0005-8

Keywords

Search

Navigation